Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine.

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in ...

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

Owkin has enticed another big pharma partner with its artificial intelligence-powered clinical development platform, Bristol-Myers Squibb, which is paying $80 million upfront to tap into its ...

Changing Faces announces new board appointments for Ascend, iOnctura, Pfizer, CAMP4 Therapeutics, and HUTCHMED in March 2025. Stay updated on the latest developments in the pharmaceutical industry.

A vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to be free of the toxicity that has scuppered earlier candidates. To be clear, there ...

UK digital health company Sensyne Health has launched a new smartphone app to help people across the diabetes spectrum manage their condition. The app – called DBm-Health – can help users to ...

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.

Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution ...

Innovent prepares to file GLP-1/glucagon agonist mazdutide in China for diabetes, its second indication after obesity.

Jazz Pharmaceuticals and Zymeworks, Inc. have announced that Jazz and Zymeworks BC, Inc. (a Zymeworks subsidiary) have entered into a licensing agreement, under which Jazz is to acquire the ...

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...